Efficacy and safety of growth hormone treatment in children with prior craniopharyngioma: An analysis of the Pharmacia and Upjohn international growth database (KIGS) from 1988 to 1996

Hormone Research

Volumn 49, Issue 2, 1998, Pages 91-97

  Price, D A ^a,g   Wilton, P ^b   Jonsson P ^b   Albertsson Wikland, K ^c   Chatelain, P ^d   Cutfield, W ^e   Ranke, M B ^f  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b PFIZER INC   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d University of Auckland ^*

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Adverse medical events; Craniopharyngioma; Growth hormone treatment; Growth response; Near final height after growth hormone treatment; Recurrence of craniopharyngioma

Indexed keywords

GROWTH HORMONE; THYROXINE;

ADOLESCENT; ARTHRALGIA; ARTICLE; BODY GROWTH; BODY HEIGHT; BONE AGE; BRAIN PSEUDOTUMOR; CANCER RECURRENCE; CANCER SURGERY; CARPAL TUNNEL SYNDROME; CONVULSION; CRANIOPHARYNGIOMA; DATA ANALYSIS; DATA BASE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; FLUID RETENTION; GROWTH HORMONE DEFICIENCY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SKULL IRRADIATION;

EID: 0031975758     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000023133     Document Type: Article

References (30)

1. Burns EC, Tanner JM, Preece MA, Cameron N: Growth hormone treatment in children with craniopharyngioma: Final height status. Clin Endocrinol 1981;14:587-595.
2. Milner RDG, Russell-Fraser T, Brook GCD, Cotes PM, Farquhar JW, Parkin JM, Preece MA, Snodgrass GJAI, Stuart Mason A, Tanner JM, Vince FP: Experience with human growth hormone in Great Britain; the report of the MRC Working Party. Clin Endocrinol 1979; 11:15-38.
3. Stahnke N, Grubel G, Lagenstein I, Willig RP: Long-term follow-up of children with craniopharyngioma. Eur J Pediatr 1984;142:179-185.
4. Price DA: Growth response in the first year of growth hormone treatment in prepubertal children with organic growth hormone deficiency: A comparison with idiopathic growth hormone deficiency. Acta Paediatr Scand Suppl 1990; 130:131-137.
5. De Vile CJ, Grant DB, Hayward RD, Stanhope R: Growth and sequelae of craniopharyngioma. Arch Dis Child 1996;75:108-114.
6. Clayton PE, Price DA, Shalet SM, Gattamaneni HR: Craniopharyngioma recurrence and growth hormone therapy (letter). Lancet 1988; i:642.
7. Wilton P: Rate of relapse of craniopharyngioma in children treated with growth hormone. Kabi International Growth Study 1992;report 8:42-47.
8. Wilton P: KIGS, the Kabi International Growth Study: Adverse events report No 6. Kabi International Growth Study 1995;report 12:41-49.
9. Tanner JM, Whitehouse RH, Takaishi M: Standards form birth to maturity for height, weight, height velocity and weight velocity: British children, 1965. Arch Dis Child 1966; 41:454-471 and 613-635.
10. Tanner JM: Fetus into Man. London, Open Books, 1978.
11. Freeman JV, Cole TJ, Chinn S, Jones PRM, White EM, Preece MA: Cross-sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 1995;73:17-24.
12. Greulich W, Pyle S: Radiographic atlas of skeletal development of the hand and wrist, ed 2. Stanford, Stanford University Press, 1959.
13. Tanner J, Whitehouse R, Marshall W, Healy M, Goldstein H: Assessment of skeletal maturity and prediction of adult height (TW2 method). London, Academic Press, 1975.
14. Ranke MB, Guilbaud O, Lindberg A, Cole T: Prediction of the growth response in children with various growth disorders treated with growth hormone: Analyses of data from the Kabi Pharmacia International Growth Study. Acta Paediatr Suppl 1993;391:82-88.
15. Graves DA: Utility of the National Cooperative Growth Study database for safety reporting. J Pediatr Suppl 1996;128:S1-S3.
16. Price DA: Characteristics and first year response to growth hormone of children with craniopharyngioma. Kabi International Growth Study 1990;report 5:25-38.
17. Lyen KR, Grant DB: Endocrine function, morbidity, and mortality after surgery for craniopharyngioma. Arch Dis Child 1982;57:837-841.
18. Sorva R, Heiskamen O: Craniopharyngioma in Finland. A study of 123 cases. Acta Neurochir (Wien) 1986;81:85-89.
19. Price DA, Ranke MB, Albertsson-Wikland K, Macs M, Wilton P: Stopping GH treatment in IGHD. Are there good reasons (abstract)? 35th Annual ESPE Meeting. Hormone Res 1996;46 (suppl 2):42.
20. Ranke MB, Jönnson P: Who stops growth hormone in KIGS, the Kabi International Growth Study - and why? Kabi International Growth Study 1995;report 12:33-39.
21. Beshyah SA, Henderson A, Niththyananthan R, Skinner E, Anyaoku V, Richmond W, Sharp P, Johnston DG: The effects of short and long term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J Clin Endocrinol Metab 1995;80:356-363.
22. Beshyah SA, Kyd P, Thomas E, Fairney A, Johnston DG: The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adult. Clin Endocrinol 1995;42:249-254.
23. Hew FL, Alford FP, Christopher M, Rantzau C, Koschmann M, Neal D, Ward G, Best JD, Clemmons DR, Sonksen PH: Effects of growth hormone deficiency and therapy in adults on skeletal muscle glucose metabolism, lipid profiles and regional body composition. Endocrinol Metab 1996;3:55-60.
24. Johannsson G, Rosen T, Lindstedt G, Bosaeus I, Bengtsson BA: Effect of 2 years of growth hormone treatment on body composition and cardiovascular risk factors in adults with growth hormone deficiency. Endocrinol Metab 1996;3:3-12.
25. Russell-Jones DL, Watts GF, Weissberger A, Naoumova R, Myers J, Thompson GR, Sonksen PH: The effect of growth-hormone replacement on serum-lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth-hormone deficient patients. Clin Endocrinol 1994;41:345-350.
26. Schoenle EJ, Zapf J, Prader A, Torresani T, Werder EA, Zachmann M: Replacement of growth hormone (GH) in normally growing GH-deficient patients operated for craniopharyngioma. J Clin Endocrinol Metab 1995;80: 374-378.
27. Price DA, Ranke MB: Final height following growth hormone treatment; in Ranke MB, Gunnarsson R (eds): Progress in Growth Hormone Therapy - 5 Years of KJGS. Mannheim, J-und-J, 1994:129-144.
28. Moshang T, Rundle AC, Graves DA, Nickas J, Johanson A, Meadows A: Brain tumor recurrence in children treated with growth hormone: The National Cooperative Growth Study experience. J Pediatr Suppl 1996;128:S4-S7.
29. Cowell CT, Dietsch S: Adverse events during growth hormone therapy. J Pediatr Endocrinol Metab 1995;8:243-252.
30. Wilton P: KIGS, the Kabi International Growth Study: Adverse events report No 5. Kabi International Growth Study 1994;report 11:47-57.